STOCK TITAN

Arcturus Therapeutics Holdings Inc. - ARCT STOCK NEWS

Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.

Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.

Key projects in Arcturus' pipeline include:

  • LUNAR-OTC for treating ornithine transcarbamylase deficiency
  • LUNAR-CF aimed at cystic fibrosis
  • LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively

Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.

Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.

Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.

Rhea-AI Summary

Arcturus Therapeutics Holdings announced the completion of enrollment for its ARCT-154 COVID-19 vaccine trial, involving over 17,000 participants, and plans to submit an Emergency Use Authorization (EUA) application with Vietnam's Ministry of Health. A Phase 3c sub-study is also underway, aiming for comparison with AstraZeneca's vaccine. Financial results for Q3 2021 show revenues of $2.4 million and a net loss of $54.1 million. Operating expenses have increased significantly, particularly in research and development, which totaled $45.4 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
none
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will announce its third quarter financial results for the period ending September 30, 2021, post-market on November 8, 2021. A conference call is scheduled for 4:30 PM EST on the same day, allowing investors to engage directly with company leaders. The company, focused on mRNA medicines, has a diverse pipeline including vaccines for COVID-19 and influenza, along with treatments for rare diseases. Investors can access the call via a provided webcast link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences earnings
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced the appointment of Dr. Nirdosh Jagota as Chief Regulatory Officer and Dr. Dushyant B. Varshney as Chief Technology Officer. Dr. Jagota brings over 30 years of regulatory experience, previously holding roles at Merck and Genentech. Dr. Varshney, with over 25 years in biotech, has a strong background in product lifecycles at organizations such as Kite Pharma and Pfizer. These additions aim to enhance Arcturus’ manufacturing capabilities and regulatory engagement as they advance their pipeline of RNA therapeutics and vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced the approval of stock options for five new employees, totaling 57,200 shares, contingent upon filing a Form S-8 Registration Statement. The options have an exercise price of $46.98, based on the closing stock price on October 15, 2021. They come with a ten-year term and vest over four years. This inducement grant is part of each individual's compensation package and supports Arcturus' focus on developing mRNA medicines, including vaccines for infectious diseases and therapies for rare liver and respiratory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
-
Rhea-AI Summary

Arcturus Therapeutics has initiated the Phase 3b dosing of ARCT-154, a self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant. This trial, approved by the Vietnam Ministry of Health, aims to enroll approximately 20,000 participants, with half receiving the vaccine. Following a review of safety data from 1,000 Phase 1/2/3a participants, the company is on track to file for Emergency Use Authorization (EUA) in December 2021. This advancement brings Arcturus closer to offering a potentially best-in-class vaccine option in Vietnam and beyond.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has met with Vietnam's President Nguyen Xuan Phuc and Vingroup's CEO Nguyen Viet Quang to discuss their recent collaboration for COVID-19 vaccine manufacturing. CEO Joseph Payne expressed optimism about expanding this collaboration, highlighting Vietnam's proactive public health strategy. This collaboration aims to support Vietnam's vaccination efforts against COVID-19 variants. Arcturus specializes in mRNA medicines and has a diverse pipeline of RNA therapeutics and vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
covid-19
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) has successfully completed the dosing of 100 participants in the Phase 1 trial for its ARCT-154 vaccine and has received approval to proceed to Phase 2 and Phase 3a. The Phase 2 trial will involve an additional 300 participants, while Phase 3a will assess safety and immunogenicity in 600 more. Phase 3b is set to begin with 20,000 participants in early October. Arcturus aims to file for Emergency Use Authorization in Vietnam by December, addressing the urgent need for effective vaccines against COVID-19 variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) will participate in Citi's 16th Annual BioPharma Virtual Conference 2021.

Founded in 2013 in San Diego, California, Arcturus is focused on clinical-stage messenger RNA medicines, particularly in infectious disease vaccines and rare liver and respiratory diseases. The company's advanced technologies include LUNAR® lipid-mediated delivery and STARR™ mRNA Technology. Arcturus has a diverse pipeline, including candidates for SARS-CoV-2, Influenza, and Ornithine Transcarbamylase Deficiency, among others.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
-
Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announces its participation in several upcoming investor and scientific conferences, showcasing its advancements in mRNA medicines for infectious diseases and rare liver and respiratory conditions. Key events include presentations at the Wells Fargo Virtual Healthcare Conference on September 10, the H.C. Wainwright Global Investment Conference on September 13, and others through September 30. Investors can access links for conference details on Arcturus’ website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
conferences
Rhea-AI Summary

Arcturus Therapeutics Holdings announced its Q2 2021 financial results, reporting $2.0 million in revenue, a decline from $2.3 million in Q2 2020. The net loss was approximately $54.6 million, or ($2.07) per share, compared to a loss of $10.3 million in the previous year. Operating expenses surged to $55.7 million, largely due to R&D investments. Arcturus is advancing its vaccine candidates, including ARCT-021 and ARCT-154, with promising NHP data. They received additional funding from Vinbiocare and have cash reserves to sustain operations for over two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags

FAQ

What is the current stock price of Arcturus Therapeutics Holdings (ARCT)?

The current stock price of Arcturus Therapeutics Holdings (ARCT) is $16.91 as of November 22, 2024.

What is the market cap of Arcturus Therapeutics Holdings (ARCT)?

The market cap of Arcturus Therapeutics Holdings (ARCT) is approximately 462.7M.

What does Arcturus Therapeutics specialize in?

Arcturus Therapeutics specializes in developing RNA-based medicines for rare diseases, particularly focusing on liver and respiratory conditions.

What are the core technologies of Arcturus Therapeutics?

Arcturus' core technologies include the LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA).

What kind of diseases is Arcturus targeting with its therapies?

Arcturus targets rare diseases such as ornithine transcarbamylase deficiency, cystic fibrosis, and viral infections like influenza and COVID-19.

What recent collaborations has Arcturus entered into?

Arcturus has recently partnered with PassPort Technologies Inc. to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics.

What is Kostaive®?

Kostaive® is the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine developed by Arcturus.

Who are Arcturus' major partners?

Arcturus collaborates globally with CSL Seqirus for mRNA vaccines and has a joint venture in Japan, ARCALIS, focusing on mRNA vaccine and therapeutic manufacturing.

What is LUNAR-OTC?

LUNAR-OTC is a therapeutic candidate in Arcturus' pipeline aimed at treating ornithine transcarbamylase deficiency.

How extensive is Arcturus' patent portfolio?

Arcturus holds over 400 patents and patent applications issued across the U.S., Europe, Japan, China, and other countries.

Where is Arcturus Therapeutics headquartered?

Arcturus is headquartered in San Diego, California.

How can I get more information about Arcturus Therapeutics?

For more detailed information, visit their official website at www.ArcturusRx.com, and connect with them on Twitter and LinkedIn.

Arcturus Therapeutics Holdings Inc.

Nasdaq:ARCT

ARCT Rankings

ARCT Stock Data

462.65M
24.80M
8.46%
90.21%
16.91%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO